Trust representatives were treated to a wonderful evening of Morris dancing with the Towersey Morris who have raised £720 for the Trust.
- Doctors should be allowed to prescribe medical cannabis
- Early warning signs of MS
- Iron levels in brain may predict future disability
The MS Trust is very disappointed that the Scottish Medicines Consortium is unable to recommend ocrelizumab as an NHS treatment for relapsing remitting MS.
- Ocrelizumab not approved for PPMS
- Solvents, smoking and MS risk
- Air pollutants not linked to MS
- Cannabis review finds benefits
The combination of exposure to chemical solvents at work, having genes associated with MS and smoking greatly increases the risk of developing multiple sclerosis according to new research.
The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment for early primary progressive MS.
NICE has approved ocrelizumab (Ocrevus) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.